The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Addressing the challenge of post-ASCT relapse in multiple myeloma & the value of precision medicine
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some insights into how the myeloma treatment landscape has transformed over the years with novel agents, and further discusses the challenge of relapse in this patient population. Dr Landgren comments on the importance of improving patient databases and using detailed cytogenetic information to better understand which patients are at risk of relapse, and further explains the value of implementing precision medicine to improve outcomes for patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials, Research Funding; Amgen: Research Funding; Merck: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials; Pfizer: Consultancy.
